Sun et al. utilized GPC3-targeted CAR-T cells overexpressing GLUT1 or AGK for the treatment of HCC, which effectively and specifically lysed GPC3-positive tumor cells in an antigen-dependent manner in vitro. This evidence concerns the gene SLC2A1 and neoplasm.